The Effect of GD-iExo-003 in Acute Ischemic Stroke

Inclusion Criteria:

* Clinical diagnosis of acute ischemic stroke
* Age 18-70 years, inclusion of both genders
* Modified Rankin Scale score before stroke of 0-1
* NIHSS score 6-20 at inclusion that did not change by ≥4 points from screening to baseline assessment.
* Time of stroke onset is known and treatment can be started between day 1 and 7 of onset.
* Confirmation of hemispheric cortical infarct with magnetic resonance imaging or computed tomography
* Subjects who received intravenous thrombolysis or underwent mechanical reperfusion are eligible if they meet all other eligibility criteria.
* Adequate hepatic and renal function: serum aspartate aminotransferase ≤2.5× upper limit of normal; serum alanine aminotransferase ≤2.5× upper limit of normal; blood urea nitrogen ≤1.25× upper limit of normal; serum creatinine ≤1.25× upper limit of normal
* Adequate cardiac function.
* Subjects or legal representative can sign the informed consent and must be willing and able to comply with all aspects of treatment and follow-up schedule.

Exclusion Criteria:

* Presence of intracranial hemorrhage on CT including hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage or hemorrhagic transformation, etc.
* Presence of a lacunar or a brainstem infarct as the etiology of current symptoms.
* Evidence of brain tumor or history of epilepsy or traumatic brain injury.
* Subjects with present malignant disease.
* Subjects with severe comorbidities including immunodeficiency or coagulation disorders.
* Subjects with Alzheimer's disease, Parkinson's disease or other degenerative neurological disease.
* Ongoing systemic infection, severe local infection or taking immunosuppressants.
* Subjects with positive hepatitis B surface antibody (HBsAg) and positive hepatitis B core antibody (HBcAb), or HBsAg-positive virus carriers, positive hepatitis C antibody, positive syphilis antibody or HIV
* Allergy to the study products.
* Documented allergies
* Participation in any clinical trial in the last 3 months
* Inability or unwillingness to comply with the study schedule
* Pregnancy, childbearing potential (unless it is certain that pregnancy is not possible), oe breast feeding
* Other serious medical or psychiatric illness that is not adequately controlled
* Other circumstances that the investigator considers inappropriate for participation in the trial.